Daphne
Lv1
80 积分
2022-08-09 加入
-
Income and investment, not energy policy, are driving GHG emission intensities
6天前
已完结
-
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial
6天前
已完结
-
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
5个月前
已完结
-
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
5个月前
已完结
-
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
5个月前
已完结
-
Atrial functional mitral regurgitation: the tip of the iceberg
5个月前
已完结
-
Microenvironmental Ammonia Enhances T cell Exhaustion in Colorectal Cancer
6个月前
已完结
-
Relationship between Gut Microbiota and Bone Health
7个月前
已完结
-
Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma
8个月前
已完结
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
8个月前
已完结